Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
7.63
+0.23 (3.11%)
Oct 15, 2026, 12:23 PM EDT - Market open
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $74.27M in the quarter ending June 30, 2026, with 88.02% growth. This brings the company's revenue in the last twelve months to $239.66M, up 110.16% year-over-year. In the year 2025, Phathom Pharmaceuticals had annual revenue of $175.11M with 216.93% growth. That makes Phathom Pharmaceuticals the 16,125th largest company in the world by revenue and 2,767th in the United States.
Revenue (ttm)
$239.66M
Revenue Growth
+110.16%
P/S Ratio
2.45
Revenue / Employee
$645,989
Employees
371
Market Cap
606.05M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 175.11M | 119.86M | 216.93% |
| Dec 31, 2024 | 55.25M | 54.57M | 8,001.47% |
| Dec 31, 2023 | 682.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Valneva SE | 163.30M |
| Crescent Biopharma | 11.88M |
| DBV Technologies | 5.04M |
| Prime Medicine | 4.07M |
| Shattuck Labs | 1.00M |
| Silence Therapeutics | 615.00K |
PHAT News
- 7 days ago - Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting - GlobeNewsWire
- 16 days ago - Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA - TheFly
- 16 days ago - Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD - GlobeNewsWire
- 4 weeks ago - PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Business Wire
- 4 weeks ago - Phathom Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Phathom Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Leerink starts Phathom Pharmaceuticals at Market Perform on limited upside - TheFly
- 5 weeks ago - Phathom Pharmaceuticals initiated with a Market Perform at Leerink - TheFly